GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Acotec Scientific Holdings Ltd (HKSE:06669) » Definitions » COGS-to-Revenue

Acotec Scientific Holdings (HKSE:06669) COGS-to-Revenue : 0.21 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Acotec Scientific Holdings COGS-to-Revenue?

Acotec Scientific Holdings's Cost of Goods Sold for the six months ended in Dec. 2023 was HK$53.0 Mil. Its Revenue for the six months ended in Dec. 2023 was HK$252.4 Mil.

Acotec Scientific Holdings's COGS to Revenue for the six months ended in Dec. 2023 was 0.21.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Acotec Scientific Holdings's Gross Margin % for the six months ended in Dec. 2023 was 78.99%.


Acotec Scientific Holdings COGS-to-Revenue Historical Data

The historical data trend for Acotec Scientific Holdings's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acotec Scientific Holdings COGS-to-Revenue Chart

Acotec Scientific Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
0.15 0.16 0.12 0.15 0.20

Acotec Scientific Holdings Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only 0.13 0.17 0.13 0.20 0.21

Acotec Scientific Holdings COGS-to-Revenue Calculation

Acotec Scientific Holdings's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=105.476 / 518.285
=0.20

Acotec Scientific Holdings's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=53.033 / 252.428
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acotec Scientific Holdings  (HKSE:06669) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Acotec Scientific Holdings's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 53.033 / 252.428
=78.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Acotec Scientific Holdings COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Acotec Scientific Holdings's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Acotec Scientific Holdings (HKSE:06669) Business Description

Traded in Other Exchanges
Address
16 North Hongda Road, 4-5th Floor, Building No. 1, Beijing Economic-Technological Development Area, Beijing, CHN
Acotec Scientific Holdings Ltd is a medical device company. The company is focused on providing leave nothing behind treatment solutions for vascular diseases. It has developed a suite of interventional medical devices featuring world- leading technologies, notably in the fields of drug-coated balloons and thrombus aspiration catheters. The company's commercialized product is Semi-compliant PTCA Balloon (YAN) is a product designed for dilation in coronary artery or coronary artery bypass vessels stenosis to improve myocardial perfusion. Geographically, the company operates from Mainland China, Europe and Other countries and regions. Majority of revenue is generated from Mainland China.
Executives
Vistra Trust (singapore) Pte. Limited 2301 Trustee
Nexus Partners Group Limited 2201 Interest of corporation controlled by you
Cosmic Elite Holdings Limited 2101 Beneficial owner
Li Jing 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L.p. 2201 Interest of corporation controlled by you
Cpe Funds Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Iii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment Ii Limited 2201 Interest of corporation controlled by you
Ca Medtech Investment (cayman) Limited 2101 Beneficial owner
Cpe Holdings Limited 2201 Interest of corporation controlled by you
Cpe Holdings International Limited 2201 Interest of corporation controlled by you
Cpe Gof Gp Limited 2201 Interest of corporation controlled by you
Cpe Global Opportunities Fund, L.p. 2201 Interest of corporation controlled by you
Boston Scientific Corporation 2201 Interest of corporation controlled by you
Cpechina Fund Iii, L. P.

Acotec Scientific Holdings (HKSE:06669) Headlines

No Headlines